Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 6/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564669 | 0.85 | BRD4 (0.38) | PIK3CAGCKBRD4 | |
| SCHEMBL564333 | 0.85 | GCK (0.39) | PIK3CAPIK3CDGPR119GCKPIK3CB | |
| SCHEMBL563822 | 0.81 | GCK (0.41) | PIK3CAGPR119GCKPIK3R1LRRK2 | |
| SCHEMBL563533 | 0.79 | PIK3CA (0.38) | PIK3CAGCKPIK3R1MTOR | |
| SCHEMBL564358 | 0.78 | GCK (0.38) | PIK3CAPIK3CDGPR119GCKRAF1 | |
| SCHEMBL564250 | 0.77 | GCK (0.36) | PIK3CAPIK3CDGPR119GCKRAF1 | |
| SCHEMBL563828 | 0.77 | GCK (0.39) | PIK3CAPIK3CDGPR119GCKRAF1 | |
| SCHEMBL564326 | 0.75 | EGFR (0.36) | PIK3CAPIK3R1TBK1 | |
| SCHEMBL564699 | 0.75 | GPR119 (0.36) | PIK3CAPIK3CDGPR119GCKRAF1 | |
| SCHEMBL564698 | 0.75 | GPR119 (0.36) | PIK3CAPIK3CDGPR119GCKRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | PIK3CA 875/4885PIK3CD 1504/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.